BioCentury
ARTICLE | Emerging Company Profile

B-ing persistent

How Aleta’s CAR T cell platform could direct CD19 CARs to any tumor type

March 17, 2017 6:47 PM UTC

Aleta Biotherapeutics Inc. is extending the use of CD19-targeting CAR T cells by coating non-B cell tumors with the antigen.

President and CSO Paul Rennert told BioCentury the key to effective CAR T cell therapies is targeting a plentiful tumor antigen that can trigger wide and persistent expansion of the T cells. ...

BCIQ Company Profiles

Cogent Biosciences Inc.

BCIQ Target Profiles

CD19

HER2